Summary

KEY FINDINGS
The Europe dry eye disease market is predicted to project a CAGR of 4.79% during the forecast period, 2023-2032. Factors such as the growing awareness regarding dry eye disease, the increasing prevalence of glaucoma, the rising geriatric population, and the surging market consolidation are predominately credited to the region’s market growth.
MARKET INSIGHTS
Poland, Spain, France, the United Kingdom, Germany, Belgium, Italy, and Rest of Europe are assessed for the Europe dry eye disease market growth evaluation. Italy harbors an advanced healthcare industry, representing a significant market. Glaucoma, as well as retinal disorders, encompass the largest segments. However, dry eye disease is relatively smaller, with no insurance reimbursement offered for the treatment of the same. The Italian Medicines Agency (Agenzia italiana del farmaco, AIFA) is the public institution in the country overlooking the regulatory activities of pharmaceuticals. Further, dry eye disease is more frequent among women in Italy, increasing with age.
In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) oversees the quality, efficacy, and safety of health products and medicines for veterinary and human use and clinical developments. In addition, according to World Health Organization (WHO) stats, health expenditure raised in the past two decades. Furthermore, the presence of ophthalmic clinics boosts the analyzed market’s demands in Belgium.
Whereas in Spain, the increasing healthcare expenditure on pharmaceutical development enables growth opportunities. Besides, approximately 42% of the population will be aged above 60 by 2050.
COMPETITIVE INSIGHTS
Leading firms operating in the market are Johnson & Johnson, VISUfarma, Novartis AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
8.1.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
8.1.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED KINGDOM
8.1.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. GERMANY
8.1.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.3. FRANCE
8.1.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.4. ITALY
8.1.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.5. BELGIUM
8.1.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.6. SPAIN
8.1.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.7. POLAND
8.1.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.8. REST OF EUROPE
8.1.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA